In conclusion, this study performed an integrative analysis of CAF cell subpopulations in CRC and demonstrated that LHFPL6 is associated with CAF-mediated tumor progression, establishing LHFPL6 as a promising prognostic biomarker and potential therapeutic target for CRC. Here, LHFPL6 is linked to colorectal carcinoma.